Sanofi (NASDAQ:SNY) Shares Sold by McClarren Financial Advisors Inc.

by · The Cerbat Gem

McClarren Financial Advisors Inc. trimmed its position in shares of Sanofi (NASDAQ:SNY – Free Report) by 90.8% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 55 shares of the company’s stock after selling 545 shares during the period. McClarren Financial Advisors Inc.’s holdings in Sanofi were worth $33,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of SNY. Price T Rowe Associates Inc. MD raised its stake in shares of Sanofi by 88.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 10,843,682 shares of the company’s stock valued at $522,991,000 after purchasing an additional 5,091,304 shares in the last quarter. Federated Hermes Inc. increased its stake in Sanofi by 58.5% during the 1st quarter. Federated Hermes Inc. now owns 3,947,583 shares of the company’s stock valued at $218,933,000 after buying an additional 1,456,269 shares during the period. Point72 Asset Management L.P. increased its stake in Sanofi by 969.6% during the 4th quarter. Point72 Asset Management L.P. now owns 950,649 shares of the company’s stock valued at $45,850,000 after buying an additional 861,770 shares during the period. Regal Partners Ltd bought a new stake in shares of Sanofi during the 4th quarter worth about $35,034,000. Finally, Vestal Point Capital LP lifted its stake in shares of Sanofi by 400.0% in the 4th quarter. Vestal Point Capital LP now owns 750,000 shares of the company’s stock worth $36,172,000 after acquiring an additional 600,000 shares during the period. 14.04% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the stock. Barclays reiterated an “overweight” rating on shares of Sanofi in a research note on Wednesday, July 2nd. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Sanofi in a research report on Tuesday. Hsbc Global Res raised Sanofi to a “strong-buy” rating in a research note on Monday, April 28th. Morgan Stanley set a $56.00 target price on Sanofi in a research note on Monday, June 2nd. Finally, BNP Paribas initiated coverage on Sanofi in a report on Tuesday, April 15th. They set an “outperform” rating and a $65.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating, four have issued a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $62.00.

View Our Latest Report on SNY

Sanofi Price Performance

Shares of NASDAQ:SNY opened at $47.84 on Wednesday. The company has a market capitalization of $117.47 billion, a PE ratio of 11.50, a price-to-earnings-growth ratio of 1.15 and a beta of 0.48. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.94 and a current ratio of 1.27. The stock has a fifty day moving average of $48.93 and a 200-day moving average of $52.06. Sanofi has a one year low of $44.73 and a one year high of $60.12.

Sanofi (NASDAQ:SNY – Get Free Report) last announced its earnings results on Thursday, July 31st. The company reported $0.90 EPS for the quarter, missing the consensus estimate of $0.96 by ($0.06). Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The company had revenue of $11.34 billion for the quarter, compared to analysts’ expectations of $9.91 billion. During the same period in the prior year, the company earned $1.73 earnings per share. The company’s revenue for the quarter was down 7.0% on a year-over-year basis. As a group, equities analysts anticipate that Sanofi will post 4.36 EPS for the current fiscal year.

Sanofi Profile

(Free Report)

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

See Also